Tahmasebivand Mahsa, Mousavi Seyyed Reza, Khorrami Mehdi, Ayromlou Hormoz, Rikhtegar Reza, Saberi Leila, Khademi Bahareh, Bahmanpour Zahra, Emamalizadeh Babak
Immunology research center, Tabriz University of medical science, Tabriz, Iran; Department of Medical Genetics, Faculty of Medicine, Tabriz university of Medical Sciences, Tabriz, Iran.
Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
J Neuroimmunol. 2020 Mar 7;342:577212. doi: 10.1016/j.jneuroim.2020.577212.
Multiple sclerosis is immune-mediated disease of the central nervous system characterized by demyelination in axons. IFN-β is first-line treatment of MS. Biomarkers are needed for early prediction of responders and non-responders to therapy in the first month of treatment to avoid further disabilities. In this study, we analyzed the expression level of miR-504 and miR-711 in 52 IFN-β responder patients in comparison to 53 non-responders. In the next step, the in-silico analysis was used to enrich related signaling pathways. The expression level of miR-504 was significantly higher in patients who respond to IFN-β therapy, compared with non-responders and we obtain related statistically significant KEGG molecular signaling pathways. Our findings suggest that miR-504 can be considered as a novel biomarker for response to IFN-b therapy.
多发性硬化症是一种中枢神经系统的免疫介导疾病，其特征是轴突脱髓鞘。干扰素-β是多发性硬化症的一线治疗药物。需要生物标志物来在治疗的第一个月早期预测治疗反应者和无反应者，以避免进一步的残疾。在本研究中，我们分析了52例干扰素-β反应者患者与53例无反应者患者中miR-504和miR-711的表达水平。在下一步中，使用计算机分析来富集相关信号通路。与无反应者相比，对干扰素-β治疗有反应的患者中miR-504的表达水平显著更高，并且我们获得了相关的具有统计学意义的KEGG分子信号通路。我们的研究结果表明，miR-504可被视为干扰素-β治疗反应的一种新型生物标志物。
